Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (Nasdaq: CMPS) reported 26-week Phase 3 COMP006 data for COMP360 psilocybin in treatment-resistant depression (TRD). In a highly chronic TRD population, 39% on 25 mg achieved ≥25% MADRS reduction at Week 6 and maintained benefit, on average, through Week 26, with a generally well-tolerated safety profile.
Nearly 30% of Week 6 responders entered remission after retreatment. A rolling NDA with the FDA is underway, with final submission targeted for Q4 2026 and a potential U.S. launch in the first half of 2027, subject to approval and DEA rescheduling.
Compass Pathways (Nasdaq: CMPS) granted new equity awards under its 2026 Inducement Plan to eight newly hired non-executive employees. Awards, granted on July 1, 2026, include options for 63,685 shares and restricted share units or UK nominal cost options for 30,300 shares.
The options have a $13.29 exercise price, matching the Nasdaq closing price on the grant date, and vest over four years (25% after one year, then monthly over three years). RSUs and nominal cost options vest in four equal annual installments. According to Compass, these awards were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment.
Compass Pathways (Nasdaq: CMPS) granted equity awards under its 2026 Inducement Plan to 17 newly hired non-executive employees. Awards, granted on June 1, 2026, include options for 157,000 shares at $14.19 and RSUs/nominal cost options for 74,700 shares, all vesting over four years under Nasdaq Rule 5635(c)(4).
Compass Pathways (Nasdaq: CMPS) elected Kathleen Tregoning to its Board of Directors at the annual general meeting. She will serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee.
According to Compass Pathways, Tregoning brings extensive biopharma experience, including senior roles at Cerevel Therapeutics, Sanofi and Biogen, plus health policy work in the U.S. Congress. The company highlights progress for its investigational therapy COMP360, including two Phase 3 trials that met their primary endpoint and a rolling NDA submission and review for treatment-resistant depression.
Compass Pathways (Nasdaq: CMPS) announced that management will attend the Jefferies Global Healthcare Conference on June 3, 2026, including a fireside chat at 12:45pm ET.
A live audio webcast and 30-day replay will be available via the Investors “Events” page on the Compass website.
Compass Pathways (Nasdaq: CMPS) announced that its management will participate in the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026. A fireside chat is scheduled for May 19 at 10:00am ET, with a live and 30-day replay webcast via the company’s investor site.
Compass Pathways (Nasdaq: CMPS) reported Q1 2026 results and regulatory milestones for COMP360 psilocybin therapy in treatment-resistant depression.
FDA granted a rolling NDA submission, with final filing targeted for Q4 2026. COMP360 also received a Commissioner’s National Priority Review Voucher, which may shorten review to 1–2 months after filing.
Q1 2026 research and development expenses were $26.5 million and general and administrative expenses were $16.4 million. Net income reached $91.2 million, mainly from a non-cash warrant fair value gain of $130.9 million. Cash and equivalents rose to $466 million, with debt at $50.5 million and cash runway expected to extend into 2028.
Compass Pathways (Nasdaq: CMPS) will release first quarter 2026 financial results and business updates on May 13, 2026. Management will host a conference call and live webcast on May 13, 2026 at 8:00 AM ET (1:00 PM UK). The webcast will be archived for 30 days.
Compass Pathways (Nasdaq: CMPS) granted inducement equity awards on May 1, 2026 to 13 newly hired non-executive employees under the 2026 Inducement Plan.
The awards include options covering an aggregate of 125,335 shares and RSUs/nominal cost options covering 59,625 shares, exercise price $9.01, vesting over up to four years, and were approved under Nasdaq Listing Rule 5635(c)(4).
Compass Pathways (Nasdaq: CMPS) announced the FDA granted a rolling NDA submission and review for COMP360 and that COMP360 received a Commissioner's National Priority Voucher (CNPV) for treatment‑resistant depression (TRD).
The CNPV offers enhanced FDA communications and a shortened 1–2 month review window after NDA filing. Compass cites positive results from two Phase 3 trials across >1,000 TRD participants and reports rapid onset (as soon as one day) and durability through six months for responders, with most treatment‑emergent adverse events mild/moderate and resolving within 24 hours.